|drug3949||n/a - samples collected along routine care samples only Wiki||0.71|
|drug1151||Educational meetings and visual prompts Wiki||0.71|
|D009101||Multiple Myeloma NIH||1.00|
|D054219||Neoplasms, Plasma Cell NIH||1.00|
|D003141||Communicable Diseases NIH||0.05|
There are 2 clinical trials
Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.
Description: The duration of infection.Measure: Nature of COVID19 Time: 1 years
Description: Costs related to Covid in terms of health resource needs.Measure: Costs related to COVID-19 Time: 1 years
Description: Number of infection recovery for each systemic anti-cancer subgroup.Measure: Systemic anti-cancer therapy subgroup Time: 1 years
Description: Evaluate if recurring haematological and chemistry values are related to infection onset, better or poorer outcome.Measure: Laboratory values collected at hospitalization Time: 1 years
Description: Number of infection in each myeloma patient subgroups and evaluation of the number of recovery per subgroup.Measure: COVID-19 infection in myeloma patient subgroups Time: 1 years
Description: Number of frail patients with COVID-19 infection and resolution of it.Measure: Incidence of COVID-19 infection in frail patients Time: 1 years
Description: Number of infection and outcome per country.Measure: Infection outcome in different countries Time: 1 years
The coronavirus (COVID-19) pandemic has brought severe challenges for myeloma patients. Myeloma patients are considered ultra-high risk for COVID-19 and fall into the strictest group for shielding. When on treatment, but also during times of active surveillance, patients have to regularly and frequently leave shielding and visit the hospital for blood tests to monitor their disese. This is specifically for quantification of circulating tumour protein biomarker tests for paraprotein (PP) and/or serum free light chains (sFLCs) by specialised biochemistry units. This research aims to evaluate the potential use of an at-home patient administered technique to sample blood. The purpose of the blood sampling technique is to monitor your disease status. We want to test if it is possible to monitor a patient's disease status using this alternative blood collection method when compared to monitoring disease status using the traditional blood collection methods (venous blood sampling). The new VAMS method is not intended to be used interchangeably or will not replace the current method. This study is to evaluate an alternative sample type that may be used to improve the patient pathway, especially during these uncertain times.
Description: Validated FLC method for use with VAMS that conforms to ISO15189:2012 accreditationMeasure: Validated FLC Time: 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports